Slide 1: Third Quarter Fiscal Year 2013 Conference Call and Webinar
Simulations Plus, Inc. (NASDAQ:SLP) Third Quarter Fiscal Year 2013 Conference Call and Webinar July 11, 2013
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such
Slide 3: SLP 3Q13 Highlights
• 3 Q13 compared to 3Q12: – 23nd consecutive profitable quarter, and 45 th of last 47 quarters – Sales up 11.7% to 3 rd Quarter Record $3.095 million from $2.772 million – Gross profit up 13.2% to $2.643 million from $2.334 million – SG&A increased 1.4% to $0.904 million from $0.891 million • As a p
Slide 4: Income Statement 3QFY13 vs. 3QFY12
Income Statement 3 QFY13 vs. 3QFY12 ($ millions) 3Q13 3Q12 Net sales 3.095 2.772 Gross profit 2.643 2.334 Gross profit margin 85.4% 84.2% SG&A 0.904 0.891 R&D 0.206 0228 Total operating expenses 1.110 1.119 Income from continuing operations 1.533 1.214 Other income 0.013 0.077 Income from continuing
Slide 5: Revenues by Quarter
Revenues by Quarter (pro forma prior to 2012) $1.4 $1.8 $2.0 $1.1 $1.7 $2.2 $2.3 $1.3 $2.1 $2.6 $2.6 $1.4 $2.2 $2.8 $2.8 $1.6 $2.3 $3.1 $3.1 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013
Slide 6: Gross Profit by Fiscal Quarter
Gross Profit by Fiscal Quarter (pro forma prior to 2012) $1.24 $1.53 $1.75 $0.71 $1.45 $1.93 $1.97 $1.07 $1.70 $2.21 $2.21 $1.12 $1.90 $2.39 $2.33 $1.32 $1.90 $2.62 $2.64 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013
Slide 7: EBITDA by Fiscal Quarter
EBITDA by Fiscal Quarter $0.55 $0.73 $0.93 $0.20 $0.73 $1.28 $1.23 $0.36 $1.00 $1.48 $1.48 $0.27 $1.23 $1.38 $1.48 $0.58 $1.09 $1.76 $1.73 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013
Slide 8: Net Income by Quarter
Net Income by Quarter (pro forma prior to 2012) $0.33 $0.47 $0.53 $0.17 $0.44 $0.85 $0.74 $0.21 $0.56 $0.91 $1.05 $0.17 $0.76 $0.84 $0.87 $0.35 $0.59 $1.06 $0.99 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013
Slide 9: New Customers by Quarter
New Customers by Quarter 10 11 9 9 14 17 12 14 15 21 13 10 18 18 16 Q1 Q2 Q3 Q4 2010 2011 2012 2013
Slide 10: Selected Balance Sheet Items
Selected Balance Sheet Items ($ millions) MAY 31, 2013 August 31, 2012 Cash and cash equivalents $10.005 $12.701 Cash per share 0.61 0.80 Total current assets 13.442 14.670 Total assets 16.403 17.347 Total current liabilities 1.030 1.415 Total liabilities 1.941 2.204 Current ratio 13.05 10.36 Shareh
Slide 11: Returning Cash to Shareholders
$1.59 $0.80 $0.80 $2.24 $0.00 $0.48 $1.97 $12.66 $13.24 $12.89 $12.70 $11.38 $9.33 $9.76 $10.00 Q4FY11 Q1FY12 Q2FY12 Q3FY12 Q4FY12 Q1FY13 Q2FY13 Q3FY13 $ Millions Dividend Paid Proceeds from Sale of Subsidiary Cash Returning Cash to Shareholders
Slide 12: Simulations Plus Products & Services
N H O OH O CH 3 CH 3 CH 3 Discovery Preclinical Clinical MedChem Studio™ MedChem Designer™ GastroPlus™ DDDPlus™ ADMET Predictor™ Simulations Plus Products & Services Consulting Services & Collaborations MembranePlus ™
Slide 13: Product News
Product News • Version 8.5 in final testing – release expected Q4FY2013 • Unique precipitation model added • Infant PBPK physiologies added – pediatrics is high - interest area in FDA and industry • Added a built - in method for transporter in vitro - in vivo extrapolation • Added a number of additi
Slide 14: Marketing and Sales Program
Marketing and Sales Program • Conferences /Scientific Meetings continue to be primary source of leads • During Q3 we did 19 scientific meetings and conferences in the U.S . and Europe, as well as numerous customer visits in Japan • Trainings and Workshops • Conducted 8 on - site training courses at
Slide 15: NCE (New Chemical Entity) Project
NCE (New Chemical Entity) Project • Highly successful malaria NCE project demonstrated the value of Simulations Plus software and consulting services for new molecule design • Seven molecules were received from synthesis and were tested against the malaria parasite. All seven showed inhibition of th
Slide 16: Summary
Summary • For 3 QFY13: - Record financial performance continues our 5 - year - plus profitable trend - Earnings growth 14.3% on 11.7% revenue growth demonstrates high margins - This is despite substantial increases in income taxes and health insurance • Continuing to Expand our Life Sciences team: -
Slide 17: simulationsplus, inc, é
simulationsplus, inc, é